Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

BioRestorative Therapies Inc

BRTX ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$0.23

▲ +2.59%

Market Cap $5.76M · Vol 33.03K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$5.76M

Micro Cap

Div Yield

N/A

EPS Growth

+68.67%

YoY

RSI (14)

29.58

Momentum

Beta

0.80

vs Market

52W High

$1.89

88.02% below

52W Low

$0.16

41.10% above

Volume

33.03K

Avg 36.08K

P/B

30.43

Price-to-book

ROE

N/A

Return on equity

Free Float

89.63%

Public shares

Shariah Compliance8 STANDARDS

✗ BioRestorative Therapies Inc (BRTX) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does BRTX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+10.74%

-31.55%

+19.59%

-20.74%

YTD

-80.69%

-84.94%

-91.57%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$359.70K
Net Income	$-14,241,980.00
Revenue Growth (YoY)	-7.32%
Gross Margin	93.37%
Operating Margin	-4,350.05%
Net Profit Margin	-3,959.40%
ROE	N/A
ROA · ROIC	-174.11% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	29.38
P/B	30.43
P/FCF	N/A
EPS Growth	+68.67%
Outstanding Shares	25.48M

Technical Indicators

50-Day SMA	$0.32
200-Day SMA	$0.61
RSI (14)	29.58
Beta	0.80
52-Week High	$1.89
52-Week Low	$0.16

Volume Today	33.03K
Avg Daily Volume (30D)	36.08K
Relative Volume	0.92x
Volatility (10D)	45.96
Volatility (30D)	63.08
Free Float	89.63%

Analyst Consensus

BUY

Current Price $0.23

Mean Target $8.00

52W Low$0.16 52W High$1.89

Current

Target

$0.16 $1.89

Current Analyst target

+3,441.39% upside potential · 2 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001S90FP6

ISINUS0906556065

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateAug 13, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

BioRestorative Therapies, Inc. is engaged in developing therapeutic products using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. It has commenced a Phase II clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The Company is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). It has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. It also operates a commercial biocosmeceutical platform.